Valuation: Delcath Systems, Inc.

Market Cap 559M 487M 460M 418M 783M 53.64B 786M 5.51B 2.13B 27.27B 2.1B 2.05B 87.75B P/E 2026 *
-107x
P/E 2027 * -201x
Enterprise Value 559M 487M 460M 418M 783M 53.64B 786M 5.51B 2.13B 27.27B 2.1B 2.05B 87.75B EV / Sales 2026 *
5.26x
EV / Sales 2027 * 4.24x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week+1.26%
Current month-2.13%
1 month-6.06%
3 months+37.81%
6 months+72.48%
Current year+59.50%
1 week 15.88
Extreme 15.88
16.51
1 month 15.68
Extreme 15.68
17.15
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
508,536,585.37
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%+1.26%+39.60%+263.66% 559M
-0.08%+0.51%+3.96%-23.82% 18.32B
-1.28%+2.56%-1.23%+7.51% 16.74B
-1.83%-0.18%-54.33%-48.76% 6.23B
+1.28%-0.54% - - 4.07B
-1.87%0.00%+31.14%+63.46% 1.89B
+0.18%+0.37%-18.66%-7.16% 1.78B
+0.11%+0.35%-50.16%-62.44% 1.09B
+1.80%+6.24%+49.06%+160.36% 942M
+3.29%-3.41% - - 271M
Average +0.07%+1.17%-0.08%+44.10% 5.19B
Weighted average by Cap. -0.58%+1.09%-5.20%-5.82%

Financials

2026 *2027 *
Net sales 106M 92.62M 87.45M 79.41M 149M 10.19B 149M 1.05B 404M 5.18B 399M 390M 16.67B 132M 115M 109M 98.68M 185M 12.66B 186M 1.3B 502M 6.44B 496M 485M 20.72B
Net income -5.72M -4.99M -4.71M -4.28M -8.01M -549M -8.05M -56.43M -21.77M -279M -21.49M -21.01M -898M -3.39M -2.95M -2.79M -2.53M -4.75M -325M -4.77M -33.42M -12.89M -165M -12.73M -12.44M -532M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-09-18 US$16.11 -0.86% 703,196
26-09-17 US$16.25 +0.18% 437,188
26-09-16 US$16.22 +0.31% 463,167
26-09-15 US$16.17 -1.64% 323,159
26-09-14 US$16.44 +3.33% 503,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.11USD
Average target price
24.00USD
Spread / Average Target
+48.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!